Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SDHB | P21912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890502 | 0.97 | PTPN1 (0.41) | PTPN1PTPN2PTPRCMAPK8MAPK9 | |
| SCHEMBL4897308 | 0.91 | PTPN1 (0.45) | PTPN1PTPN2PTPRCL3MBTL1 | |
| SCHEMBL4898600 | 0.91 | PTPN1 (0.39) | PTPN1PTPN2PTPRCPTGS2NR1H2 | |
| SCHEMBL4893823 | 0.90 | PTPN1 (0.41) | PTPN1PTPN2PTPRCPTGS2NR1H2 | |
| SCHEMBL4901377 | 0.87 | MKNK1 (0.37) | PTPN1PTPN2PTGS2 | |
| SCHEMBL4901303 | 0.87 | PTPN1 (0.46) | PTPN1PTPN2PTPRCMAPK8MAPK10 | |
| SCHEMBL4899373 | 0.87 | PTPN1 (0.44) | PTPN1PTPN2PTPRCPTGS2NR1H2 | |
| SCHEMBL4892091 | 0.86 | PTPN1 (0.42) | PTPN1PTPN2PTPRCL3MBTL1 | |
| SCHEMBL4895547 | 0.85 | MAPK8 (0.43) | PTPN1PTPN2PTPRCMAPK8MAPK10 | |
| SCHEMBL4898664 | 0.84 | PTPN1 (0.45) | PTPN1PTPN2PTPRCMAPK10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | PTPN1 13/4885PTPN2 27/4885PTPRC 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.